{
  "symbol": "MDWD",
  "company_name": "Mediwound Ltd Ord Sh",
  "ir_website": "https://ir.mediwound.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update",
          "url": "https://ir.mediwound.com/news-releases/news-release-details/mediwound-reports-third-quarter-2024-financial-results-and",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.mediwound.com)\n\nMENU\n\nSearch:\n\nSearch for:\n\nMENU\n\n# Press Release Details\n\n## Website Notice Block\n\n## \n\nMediWound Reports Third Quarter 2024 Financial Results and Provides Company Update\n\nNovember 26, 2024\n\n[PDF Version](/node/11411/pdf)\n\n_EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025_\n\n_FDA Approves NexoBrid for Pediatric Use_\n\n_$25 Million Financing and ‚Ç¨16.25 Million EIC Funding Strengthen Cas_ _h Runway to Profitability_\n\n_NexoBrid Product Revenue Meets Expectations; Demand Exceeds Capacity as New Manufacturing Facility Commissioning Underway_\n\n_Conference Call Today, November 26 at 8:30 a.m. Eastern Time_\n\nYAVNE, Israel, Nov. 26, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update.\n\n‚ÄúWe made great headway toward our objectives this quarter, achieving a major milestone with NexoBrid approval for pediatric use in the U.S.,‚Äù said Ofer Gonen, Chief Executive Officer of MediWound. ‚ÄúWith the upcoming launch of the Phase 3 trial for EscharEx in venous leg ulcers, we‚Äôre advancing closer to addressing critical unmet needs in a $2 billion market. Additionally, we will be conducting a head-to-head Phase 2 study vs. collagenase in 2025, to further demonstrate EscharEx‚Äôs competitive advantage and maximize its commercial opportunity. We‚Äôre also accelerating our diabetic foot ulcer program with Phase 2/3 preparations well underway. Our manufacturing expansion remains on track, positioning us to meet the growing demand for NexoBrid globally.‚Äù\n\n**Third Quarter 2024 Highlights, Recent Developments and Upcoming Milestones:**\n\n**NexoBrid**\n\n  * Completed construction of the Company‚Äôs new, state-of-the-art GMP-compliant manufacturing facility with commissioning underway. The facility is expected to reach full operational capacity by the end of 2025, increasing manufacturing output sixfold. Commercial availability will depend on securing the necessary regulatory approvals.\n\n\n  * Received U.S. Food and Drug Administration (FDA) approval of NexoBrid for pediatric patients aged newborn through 18 with deep partial-thickness and/or full-thickness thermal burns. NexoBrid is now authorized for use in the U.S. for all age groups, aligning with its indications in the European Union and Japan.\n\n\n  * U.S. launch by Vericel continues to gain traction, with over 70 burn center Pharmacy and Therapeutics (P&T) committee submissions, of which approximately 50 have received approval and have placed initial orders. NexoBrid received a Category III CPT code, which will be posted on the AMA website on January 1, 2025, and will go into effect on July 1, 2025.\n\n\n  * The World Health Organization (WHO) has recently recognized enzymatic debridement as a validated treatment for burn injuries. This recognition, featured in the WHO‚Äôs _Standards and Recommendations for Burns Care in Mass Casualty Incidents (BMCI)_ guidelines for emergency medical teams, highlights NexoBrid‚Äôs critical role in emergency preparedness. It also bolsters efforts to implement strategic stockpiling plans within the European Union through the Health Emergency Preparedness and Response Authority (HERA), following the precedent set by the U.S. Biomedical Advanced Research and Development Authority (BARDA).\n\n\n  * The Company anticipates $20 million in total revenue for 2024, compared to prior guidance of $24 million. NexoBrid product revenues remain in line with expectations, driven by strong demand that exceeds current manufacturing capacity. Following FDA approval of NexoBrid‚Äôs pediatric indication without additional post-approval requirements, BARDA funding for further development is no longer required, reducing expected revenue from development services. Additionally, based on a Type C meeting with the FDA regarding the NexoBrid temperature-stable formulation project for the U.S. Army, clinical activities have been scheduled for 2026, which affects anticipated revenue from the U.S. Department of Defense for 2024.\n\n\n\n**EscharEx**\n\n  * The Phase 3 study of EscharEx for venous leg ulcers (VLUs) is set to commence, with FDA IND submission planned by year-end. All setup activities for initiation are complete, and the Company has successfully passed the required EMA inspection in preparation for the trial.\n\n\n  * The Company plans to host a virtual KOL event on January 8, 2025. The event will provide an update on the EscharEx VLU Phase 3 trial and review the commercial opportunity.\n\n\n  * Announced a planned randomized, head-to-head Phase 2 study of EscharEx vs. collagenase in VLU patients. Set to begin in 2025, the trial will support the EscharEx Biologics License Application (BLA) submission and strengthen the Company‚Äôs commercialization strategy. MediWound has secured additional R&D collaborations for this study with Solventum and M√∂lnlycke to optimize trial consistency and patient outcomes.\n\n\n  * Obtained ‚Ç¨16.25 million in funding from the European Innovation Council (EIC) for the clinical development of EscharEx for treating diabetic foot ulcers (DFUs). This will expedite MediWound's DFU program, and its associated revenue projections by four years. DFUs are more prevalent than VLUs, with a higher percentage of patients requiring debridement. Preparations for the DFU Phase 2/3 study are progressing as planned.\n\n\n\n**Corporate Development**\n\n  * Raised $25 million in a strategic private investment in public equity (PIPE) with several new and existing investors. M√∂lnlycke Health Care, a global leader in innovative wound care solutions, led the PIPE and entered into a collaboration agreement with MediWound.\n\n\n\n**Third Quarter 2024 Financial Highlights**\n\n  * **Revenue** : Revenue for the third quarter of 2024 totaled $4.4 million, compared to $4.8 million in the same period of 2023. The decrease was primarily due to lower revenue from BARDA development services.\n\n\n  * **Gross Profit** : Gross profit for the third quarter of 2024 was $0.7 million, representing 16% of total revenue, compared to $0.9 million, representing 19% of total revenue in the third quarter of 2023. This decline in gross margin reflects a shift in the revenue mix.\n\n\n  * **Expenditures** : \n    * **Research and Development** : R&D expenses for the quarter were $2.5 million, compared to $1.5 million in the third quarter of 2023. The increase was mainly due to costs associated with the EscharEx Phase 3 clinical trial.\n    * **Selling, General, and Administrative** : SG&A expenses for the third quarter of 2024 were $3.2 million, compared to $2.6 million in the same period of 2023. The increase was primarily from share-based compensation costs.\n\n\n  * **Operating Results** : Operating loss for the third quarter of 2024 was $5.1 million, compared to a loss of $3.0 million in the third quarter of 2023.\n\n\n  * **Net Loss** : Net loss for the third quarter of 2024 was $10.3 million, or $0.98 per share, compared to a net loss of $2.2 million, or $0.24 per share, in the third quarter of 2023. This change was primarily due to financial expenses driven by the revaluation of warrants.\n\n\n  * **Non-GAAP Adjusted EBITDA** : Adjusted EBITDA was a loss of $3.7 million, compared to a loss of $2.6 million in the third quarter of 2023.\n\n\n\n**Year-to-Date 2024 Financial Highlights**\n\n  * **Revenue:** Total revenues for the first nine months of 2024 reached $14.4 million, up from $13.3 million in the same period of 2023. The increase is mainly attributed to revenue contribution from Vericel.\n\n\n  * **Gross Profit** : Gross profit was $1.7 million, or 12% of total revenue, compared to $2.9 million, or 21% of total revenue, in the first nine months of 2023, reflecting changes in the revenue mix.\n\n\n  * **Expenditures** : \n    * **Research and Development** : R&D expenses were $5.9 million, slightly higher than $5.7 million in the same period of 2023.\n    * **Selling, General, and Administrative** : SG&A expenses totaled $9.1 million, compared to $8.8 million in the first nine months of 2023, driven primarily by increased share-based compensation costs.\n\n\n  * **Operating Results:** Operating loss for the first nine months of 2024 was $13.3 million, compared to $11.4 million in 2023.\n\n\n  * **Net Loss:** The net loss for the period was $26.3 million, or $2.72 per share, compared to a net loss of $5.0 million, or $0.56 per share, in the same period of 2023. This $21.3 million increase was mainly driven by net financial expenses, largely resulting from the revaluation of warrants due to a 78% rise in the Company‚Äôs share price year to date.\n\n\n  * **Adjusted EBITDA:** Adjusted EBITDA for the first nine months was a loss of $9.9 million, compared to a loss of $9.0 million in 2023.\n\n\n\n**Balance Sheet Highlights**\n\nAs of September 30, 2024, the Company had cash and cash equivalents and deposits totaling $46.0 million, compared to $42.1 million on December 31, 2023. During the first nine months of 2024, the Company raised $25 million through a PIPE offering, received $1.2 million from the exercise of Series A warrants, and fully settled its liability with Teva. The Company used $19.7 million to fund its operations in the first nine months of 2024, including $6.0 million allocated to CAPEX, primarily for facility scale-up.\n\n**Conference Call**\n\nMediWound management will host a conference call for investors on Tuesday, November 26, 2024, beginning at 8:30 a.m., Eastern Time to discuss these results. Shareholders and other interested parties may participate in the conference call by dialing 1-833-630-1956 (in the U.S.), 1-80-921-2373 (Israel), or 1-412-317-1837 (outside the U.S. & Israel). The call will be available via webcast by [clicking HERE](https://www.globenewswire.com/Tracker?data=WAjeaDlM_x64PHzsIogbzEV1Pnv5OBzU_syabYAIvNZ2MgyG4dctKwm27p7yECDNsAN9W3tOGOsnw16msKZQ913vGxv_7p9ExhRScXxzhFe8sG1SWdZG5Y7oM0y5Ruk0) or on the [Events & Presentations](https://www.globenewswire.com/Tracker?data=Io-jwu4cOqxKvr2fcbukejCqreGbw1lWAkdrXS_aeFfovdqlbMVpiehY4zApcDRUqatIMtbtxPWpix9ITBs2yxd-LrspDeNYqeJyXsn1MI4Hbpo17oTyj4-NywfTWTzeRGElMgEd394tfyt3lS1GUg==) page of Company‚Äôs website.\n\nA replay of the call will be available on the Company‚Äôs website at [www.mediwound.com](https://www.globenewswire.com/Tracker?data=SvpRtJZn5ZEnu5Lp_XmP3Wg7SJCODLCDnnia-NHxpK1QNpJUHpNgN1ejR-tdVDcXAedf8paeVDA5NFFPJToR50ujPxwDbwTtlY0NmMJ3Ov0=).\n\n**Non-IFRS Financial Measures**\n\nTo supplement consolidated financial statements prepared and presented in accordance with IFRS, the Company has provided a supplementary non-IFRS measure to consider in evaluating the Company‚Äôs performance. Management uses Adjusted EBITDA, which it defines as earnings before interest, taxes, depreciation and amortization, impairment, one-time expenses, restructuring and share-based compensation expenses.\n\nAlthough Adjusted EBITDA is not a measure of performance or liquidity calculated in accordance with IFRS, we believe the non-IFRS financial measures we present provide meaningful supplemental information regarding our operating results primarily because they exclude certain non-cash charges or items that we do not believe are reflective of our ongoing operating results when budgeting, planning and forecasting and determining compensation, and when assessing the performance of our business with our senior management.\n\nHowever, investors should not consider these measures in isolation or as substitutes for operating income, cash flows from operating activities or any other measure for determining the Company‚Äôs operating performance or liquidity that is calculated in accordance with IFRS. In addition, because Adjusted EBITDA is not calculated in accordance with IFRS, it may not necessarily be comparable to similarly titled measures employed by other companies. The non-IFRS measures included in this press release have been reconciled to the IFRS results in the tables below.\n\n**About MediWound**\n\nMediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.\n\nMediWound‚Äôs first drug, NexoBrid¬Æ, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx¬Æ, a promising candidate currently in Phase 3 development for the debridement of chronic wounds. Phase 2 clinical trials have shown EscharEx has distinct advantages over the current $360+ million market leader, presenting a unique opportunity for significant market growth.\n\nFor more information visit [www.mediwound.com](https://www.globenewswire.com/Tracker?data=SvpRtJZn5ZEnu5Lp_XmP3azT5AH0JlDL8hz5ykdHhvzKFI6D0n7rNh69Ur-zRo9YPXV3Td39uS4dP-MPVpKT843UOZSUuCw7d6eR7daRyQI=) and follow us on [LinkedIn](https://www.globenewswire.com/Tracker?data=3oKJShiERyOZR5y_gHRnYiBmNb7BzLrFK21-2hc8dwtVtxXLcBPiho655fxGFf-MjwruHUNXvsNfN82aOlJPjX8UT6svswC1cydoM0_3-hY=).\n\n**Cautionary Note Regarding Forward-Looking Statements**\n\nMediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as ‚Äúanticipates,‚Äù ‚Äúintends,‚Äù ‚Äúestimates,‚Äù ‚Äúplans,‚Äù ‚Äúexpects,‚Äù ‚Äúcontinues,‚Äù ‚Äúbelieve,‚Äù ‚Äúguidance,‚Äù ‚Äúoutlook,‚Äù ‚Äútarget,‚Äù ‚Äúfuture,‚Äù ‚Äúpotential,‚Äù ‚Äúgoals‚Äù and similar words or phrases, or future or conditional verbs such as ‚Äúwill,‚Äù ‚Äúwould,‚Äù ‚Äúshould,‚Äù ‚Äúcould,‚Äù ‚Äúmay,‚Äù or similar expressions.\n\nSpecifically, this press release contains forward-looking statements concerning the anticipated progress, development, study design, expected data timing, objectives anticipated timelines, expectations and commercial potential of our products and product candidates, including EscharEx¬Æ and NexoBrid¬Æ. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission by the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our products and products; our expectations regarding future growth, including our ability to develop new products; market acceptance of our products and product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future.\n\nThese and other significant factors are discussed in greater detail in MediWound‚Äôs annual report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (‚ÄúSEC‚Äù) on March 21, 2024 and Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound‚Äôs current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.\n\n**MediWound Contacts:**  \n---  \nHani Luxenburg| Daniel Ferry  \nChief Financial Officer | Managing Director  \nMediWound Ltd.| LifeSci Advisors, LLC  \nir@mediwound.com| daniel@lifesciadvisors.com  \n**Media Contact:**  \nEllie Hanson  \nFINN Partners for MediWound  \nellie.hanson@finnpartners.com  \n+1-929-588-2008  \n  \n**MediWound, Ltd.**  \n---  \n**Unaudited Condensed Consolidated Statements of Financial Position** U.S. dollars in thousands  \n**September 30,**| **December 31,**  \n**2024**| **2023**| **2023**  \n** _CURRENT ASSETS:_**  \nCash and cash equivalents and short-term deposits| 45,562| 45,523| 41,708  \nTrade and other receivable| 5,304| 4,071| 5,141  \nInventories| 3,022| 3,656| 2,846  \n**Total current assets**| **53,888**| **53,250**| **49,695**  \n** _NON-CURRENT ASSETS_**  \nTrade and other receivables| 50| 50| 233  \nLong-term restricted bank deposits| 434| 433| 440  \nProperty, plant and equipment, net| 13,453| 6,437| 9,228  \nRight of use assets, net| 6,793| 6,665| 6,698  \nIntangible assets, net| 116| 182| 165  \n**Total non-current assets**| **20,846**| **13,767**| **16,764**  \n**Total assets**| **74,734**| **67,017**| **66,459**  \n** _CURRENT LIABILITIES:_**  \nCurrent maturities of long-term liabilities| 726| 1,692| 1,410  \nWarrants, net| 19,056| 8,901| 7,296  \nTrade payables and accrued expenses| 3,131| 3,680| 5,528  \nOther payables| 2,664| 3,069| 3,891  \n**Total current liabilities**| **25,577**| **17,342**| **18,125**  \n** _NON- CURRENT LIABILITIES:_**  \nLiabilities in respect of IIA grants| 8,046| 7,860| 7,677  \nLiabilities in respect of TEVA| -| 2,394| 2,256  \nLease liabilities| 6,460| 5,935| 6,350  \nSeverance pay liability, net| 416| 436| 456  \n**Total non-current liabilities**| **14,922**| **16,625**| **16,739**  \nShareholders' equity| 34,235| 33,050| 31,595  \n**Total liabilities & shareholder equity**| **74,734**| **67,017**| **66,459**  \n  \n**MediWound, Ltd.**  \n---  \n**Unaudited Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss** U.S. dollars in thousands (except of share and per share data)  \n**Nine months ended**| **Three months ended**| **Year ended**  \n**September 30,**| **September 30,**| **December 31,**  \n**2024**| **2023**| **2024**| **2023**| **2023**  \nTotal Revenues| 14,382| 13,348| 4,355| 4,776| 18,686  \nCost of revenues| 12,651| 10,489| 3,678| 3,880| 15,108  \n**Gross profit**| **1,731**| **2,859**| **677**| **896**| **3,578**  \nResearch and development| 5,892| 5,659| 2,524| 1,533| 7,467  \nSelling and Marketing| 3,466| 3,635| 1,063| 1,197| 4,844  \nGeneral and administrative| 5,672| 5,185| 2,171| 1,415| 6,768  \nOther Income| -| (224)| -| (224)| (211)  \n**Total operating expenses**| **15,030**| **14,255**| **5,758**| **3,921**| **18,868**  \n**Operating loss**| **(13,299)**| **(11,396)**| **(5,081)**| **(3,025)**| **(15,290)**  \nFinancial income (expenses), net| (12,974)| 6,488| (5,180)| 877| 8,759  \nTaxes on income| (43)| (65)| (21)| (48)| (185)  \n**Net loss**| **(26,316)**| **(4,973)**| **(10,282)**| **(2,196)**| **(6,716)**  \nForeign currency translation adjustments| 3| (2)| (7)| 7| (13)  \n**Total comprehensive loss**| **(26,313)**| **(4,975)**| **(10,289)**| **(2,189)**| **(6,729)**  \n_Basic and diluted loss per share:_  \nNet loss per share| (2.72)| (0.56)| (0.98)| (0.24)| (0.75)  \nWeighted average number of ordinary shares| 9,679,599| 8,943,205| 10,511,288| 9,217,390| 9,013,144  \n  \n**MediWound, Ltd.**  \n---  \n**Unaudited Condensed Consolidated Statements of Cash Flows** U.S. dollars in thousands  \n**Nine months ended**| **Three months ended**| **Year Ended**  \n**September 30,**| **September 30,**| **December 31,**  \n**2024**| **2023**| **2024**| **2023**| **2023**  \n** _Cash Flows from Operating Activities:_**  \nNet loss| **(26,316****)**| **(4,973****)**| **(10,282****)**| **(2,196****)**| **(6,716****)**  \nAdjustments to reconcile net loss to net cash used in operating activities:  \n**Adjustments to profit and loss items:**  \nDepreciation and amortization| 1,086| 957| 361| 339| 1,303  \nShare-based compensation| 2,316| 1,642| 1,046| 311| 1,940  \nRevaluation of warrants accounted at fair value| 12,668| (6,705)| 4,661| (782)| (8,310)  \nRevaluation of liabilities in respect of IIA grants| 711| 709| 241| 217| 427  \nRevaluation of liabilities in respect of TEVA| 770| 357| 564| 116| 468  \nFinancing income (expenses) and exchange differences of lease liability| 238| (206)| 221| (184)| 257  \nIncrease (decrease) in severance liability, net| (46)| 80| (94)| 13| 83  \nOther income| -| (224)| -| (224)| (211)  \nFinancial income, net| (1,486)| (1,395)| (568)| (390)| (2,231)  \nUn-realized foreign currency (gain) loss| 74| 534| (4)| 68| 189  \n**16,331**| **(4,251****)**| **6,428**| **(516****)**| **(6,085****)**  \n**Changes in asset and liability items:**  \nDecrease (increase) in trade receivables| 285| 6,186| (468)| 71| 5,658  \nDecrease (increase) in inventories| (161)| (1,688)| 184| (526)| (906)  \nDecrease (increase) in other receivables| (283)| (198)| 291| (320)| (894)  \nDecrease in trade payables and accrued expenses| (1,948)| (1,687)| (48)| (51)| (594)  \nIncrease (decrease) in other payables| 105| (1,239)| 139| 287| (928)  \n**(2,002****)**| **1,374**| **98**| **(539****)**| **2,336**  \n**Net cash used in operating activities**| **(11,987****)**| **(7,850****)**| **(3,756****)**| **(3,251****)**| **(10,465****)**  \n  \n**Unaudited Condensed Consolidated Statements of Cash Flows** U.S. dollars in thousands  \n---  \n**Nine months ended**| **Three months ended**| **Year Ended**  \n**September 30,**| **September 30,**| **December 31,**  \n**2024**| **2023**| **2024**| **2023**| **2023**  \n** _Cash Flows from Investment Activities:_**  \nPurchase of property and equipment| (5,467)| (4,255)| (1,192)| (1,685)| (6,464)  \nInterest received| 1,588| 1,225| 461| 346| 1,947  \nInvestment in short term bank deposits, net| (9,346)| (36,319)| (13,555)| (4,489)| (29,804)  \n**Net cash used in investing activities**| **(13,225****)**| **(39,349****)**| **(14,286****)**| **(5,828****)**| **(34,321****)**  \n**_Cash Flows from Financing Activities:_**  \nRepayment of lease liabilities| (686)| (574)| (228)| (240)| (778)  \nProceeds from exercise of warrants| 1,210| -| 600| -| -  \nProceeds from issuance of shares and warrants, net| 22,436| 24,909| 22,436| -| 24,909  \nRepayments of IIA grants, net| (219)| (380)| (99)| (70)| (380)  \nRepayment of liabilities in respect of TEVA| (2,834)| (834)| (2,000)| (417)| (834)  \n**Net cash provided by (used in) financing activities**| **19,907**| **23,121**| **20,709**| **(727****)**| **22,917**  \nExchange rate differences on cash and cash equivalent balances| **(86****)**| **(538****)**| **18**| **(81****)**| **(160****)**  \nIncrease (decrease) in cash and cash equivalents| **(5,391****)**| **(24,616****)**| **2,685**| **(9,887****)**| **(22,029****)**  \nBalance of cash and cash equivalents at the beginning of the period| 11,866| 33,895| 3,790| 19,166| 33,895  \n**Balance of cash and cash equivalents at the end of the period**| **6,475**| **9,279**| **6,475**| **9,279**| **11,866**  \n  \n**MediWound Ltd.****Adjusted EBITDA** U.S. dollars in thousands  \n---  \n**Nine months ended**| **Three months ended**| **Year Ended**  \n**September 30,**| **September 30,**| **December 31,**  \n**2024**| **2023**| **2024**| **2023**| **2023**  \n**Net loss**| **(26,316****)**| **(4,973****)**| **(10,282****)**| **(2,196****)**| **(6,716****)**  \nAdjustments:  \nFinancial income (expenses), net| (12,974)| 6,488| (5,180)| 877| 8,759  \nOther Income, net| -| 224| -| 224| 211  \nTaxes on income| (43)| (65)| (21)| (48)| (185)  \nDepreciation and amortization| (1,086)| (957)| (361)| (339)| (1,303)  \nShare-based compensation expenses| (2,316)| (1,642)| (1,046)| (311)| (1,940)  \nTotal adjustments| (16,419)| 4,048| (6,608)| 403| 5,542  \n**Adjusted EBITDA**| **(9,897****)**| **(9,021****)**| **(3,674****)**| **(2,599****)**| **(12,258****)**  \n  \n![](https://ml.globenewswire.com/media/OWU0Mzg3MmItOThkNi00ZmRmLWJjYWMtYTI0YmRmMTBjZTMzLTEwMjg0MzQ=/tiny/MediWound-Ltd-.png)\n\n  * [Print Page]()\n\nPrint Page\n\n  * [Email Alerts](/email-alerts)\n\nEmail Alerts\n\n  * [IR Search](/search)\n\nIR Search\n\n\n\n\nCookie Consent\n\nBy continuing browsing, you agree to the storing of cookies on your device to enhance your site experience and for analytical purposes. To learn more about how we use the cookies, please see our [Cookie Policy](https://www.mediwound.com/cookie-policy/). \n\nI AGREE\n\nAccesi _b_ ility\n\n  * X+-\n\nFonts size\n\n  * +\n\nUnderline links\n\n  * +\n\nBigger tabs outline\n\n  * +\n\nDark contrast\n\n  * +\n\nBright contrast\n\n  * +\n\nSimple font\n\n  * +\n\nDyslexic font\n\n  * +\n\nStop animations\n\n\n\n"
        },
        {
          "title": "MediWound to Report Third Quarter 2024 Financial Results",
          "url": "https://ir.mediwound.com/news-releases/news-release-details/mediwound-report-third-quarter-2024-financial-results",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.mediwound.com)\n\nMENU\n\nSearch:\n\nSearch for:\n\nMENU\n\n# Press Release Details\n\n## Website Notice Block\n\n## \n\nMediWound to Report Third Quarter 2024 Financial Results\n\nNovember 12, 2024\n\n[PDF Version](/node/11366/pdf)\n\n### Conference Call and Webcast Scheduled for Tuesday, November 26, 2024, at 8:30 a.m. Eastern Time\n\nYAVNE, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2024, on Tuesday, November 26, 2024.\n\nFollowing the release, MediWound‚Äôs management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates.\n\nDial-in and call details are as follows:\n\n_Conference Call & Webcast Details_  \n---  \nToll-Free:| 1-833-630-1956  \nIsrael:| 1-80-921-2373  \nInternational:| 1-412-317-1837  \nWebcast:| [Click HERE](https://edge.media-server.com/mmc/p/cypnq2ht/)  \n  \nTo access the call, participants should dial the applicable telephone number above **at least 5 minutes** prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.\n\n**About MediWound**\n\nMediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.\n\nMediWound‚Äôs first drug, NexoBrid¬Æ, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx¬Æ, a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx has distinct advantages over the current $360+ million market leader, presenting a unique opportunity for significant market growth.\n\nFor more information visit [_www.mediwound.com_](https://www.globenewswire.com/Tracker?data=mE4tWUO-dMCAJwA4NOIv0jnKUKvGlaLF_DmFb4Zdn3I5em9pUdGqGoOBz8gXijY-J85hSXwnseMof2klfYv77Rp7oxRaRfbvlI485yEp_gQ=) and follow us on [_LinkedIn_](https://www.globenewswire.com/Tracker?data=pbRtC10gzGqPu4tpBsfRkuvjmAaDqKIyv4o3CXVC8EyxA0MZ-eSca0soBCKKNi1F-dlGSQvRGqnW_x5_YHnkCL1tFeitRL3Se6_StXaGdio=)**.**\n\n**MediWound Contacts:**  \n---  \nHani Luxenburg| Daniel Ferry  \nChief Financial Officer| Managing Director  \nMediWound Ltd.| LifeSci Advisors, LLC  \nir@mediwound.com| daniel@lifesciadvisors.com  \n**Media Contact:**  \nEllie Hanson  \nFINN Partners for MediWound  \nellie.hanson@finnpartners.com  \n+1-929-588-2008  \n  \n![](https://ml.globenewswire.com/media/MjIzMDBkMDgtMzA0MC00ZDVkLTg2NmMtMjYyZTg5OTM5MmRhLTEwMjg0MzQ=/tiny/MediWound-Ltd-.png)\n\n  * [Print Page]()\n\nPrint Page\n\n  * [Email Alerts](/email-alerts)\n\nEmail Alerts\n\n  * [IR Search](/search)\n\nIR Search\n\n\n\n\nCookie Consent\n\nBy continuing browsing, you agree to the storing of cookies on your device to enhance your site experience and for analytical purposes. To learn more about how we use the cookies, please see our [Cookie Policy](https://www.mediwound.com/cookie-policy/). \n\nI AGREE\n\nAccesi _b_ ility\n\n  * X+-\n\nFonts size\n\n  * +\n\nUnderline links\n\n  * +\n\nBigger tabs outline\n\n  * +\n\nDark contrast\n\n  * +\n\nBright contrast\n\n  * +\n\nSimple font\n\n  * +\n\nDyslexic font\n\n  * +\n\nStop animations\n\n\n\n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "Q3 MediWound 2024 Conference Call",
          "url": "https://ir.mediwound.com/events/event-details/q3-mediwound-2024-conference-call",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.mediwound.com)\n\nMENU\n\nSearch:\n\nSearch for:\n\nMENU\n\n# Event Details\n\n## Website Notice Block\n\n## Q3 MediWound 2024 Conference Call\n\nNovember 26, 2024 at 8:30 AM EST \n\n[Listen to Webcast](https://edge.media-server.com/mmc/p/cypnq2ht)\n\n  * [Print Page]()\n\nPrint Page\n\n  * [Email Alerts](/email-alerts)\n\nEmail Alerts\n\n  * [IR Search](/search)\n\nIR Search\n\n\n\n\nCookie Consent\n\nBy continuing browsing, you agree to the storing of cookies on your device to enhance your site experience and for analytical purposes. To learn more about how we use the cookies, please see our [Cookie Policy](https://www.mediwound.com/cookie-policy/). \n\nI AGREE\n\nAccesi _b_ ility\n\n  * X+-\n\nFonts size\n\n  * +\n\nUnderline links\n\n  * +\n\nBigger tabs outline\n\n  * +\n\nDark contrast\n\n  * +\n\nBright contrast\n\n  * +\n\nSimple font\n\n  * +\n\nDyslexic font\n\n  * +\n\nStop animations\n\n\n\n"
        },
        {
          "title": "H.C. Wainwright 26th Annual Global Investment Conference",
          "url": "https://journey.ct.events/view/3d310032-fcf1-4bb7-ae47-cf6689e3a48a",
          "content": "An error has occurred. This application may no longer respond until reloaded. [Reload]() üóô\n"
        },
        {
          "title": "Q2 MediWound 2024 Conference Call",
          "url": "https://ir.mediwound.com/events/event-details/q2-mediwound-2024-conference-call",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.mediwound.com)\n\nMENU\n\nSearch:\n\nSearch for:\n\nMENU\n\n# Event Details\n\n## Website Notice Block\n\n## Q2 MediWound 2024 Conference Call\n\nAugust 14, 2024 at 8:30 AM EDT \n\n[Listen to Webcast](https://edge.media-server.com/mmc/p/wvfc4buf)\n\n  * [Print Page]()\n\nPrint Page\n\n  * [Email Alerts](/email-alerts)\n\nEmail Alerts\n\n  * [IR Search](/search)\n\nIR Search\n\n\n\n\nCookie Consent\n\nBy continuing browsing, you agree to the storing of cookies on your device to enhance your site experience and for analytical purposes. To learn more about how we use the cookies, please see our [Cookie Policy](https://www.mediwound.com/cookie-policy/). \n\nI AGREE\n\nAccesi _b_ ility\n\n  * X+-\n\nFonts size\n\n  * +\n\nUnderline links\n\n  * +\n\nBigger tabs outline\n\n  * +\n\nDark contrast\n\n  * +\n\nBright contrast\n\n  * +\n\nSimple font\n\n  * +\n\nDyslexic font\n\n  * +\n\nStop animations\n\n\n\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Q3 MediWound 2024 Conference Call",
          "url": "https://ir.mediwound.com/events/event-details/q3-mediwound-2024-conference-call",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.mediwound.com)\n\nMENU\n\nSearch:\n\nSearch for:\n\nMENU\n\n# Event Details\n\n## Website Notice Block\n\n## Q3 MediWound 2024 Conference Call\n\nNovember 26, 2024 at 8:30 AM EST \n\n[Listen to Webcast](https://edge.media-server.com/mmc/p/cypnq2ht)\n\n  * [Print Page]()\n\nPrint Page\n\n  * [Email Alerts](/email-alerts)\n\nEmail Alerts\n\n  * [IR Search](/search)\n\nIR Search\n\n\n\n\nCookie Consent\n\nBy continuing browsing, you agree to the storing of cookies on your device to enhance your site experience and for analytical purposes. To learn more about how we use the cookies, please see our [Cookie Policy](https://www.mediwound.com/cookie-policy/). \n\nI AGREE\n\nAccesi _b_ ility\n\n  * X+-\n\nFonts size\n\n  * +\n\nUnderline links\n\n  * +\n\nBigger tabs outline\n\n  * +\n\nDark contrast\n\n  * +\n\nBright contrast\n\n  * +\n\nSimple font\n\n  * +\n\nDyslexic font\n\n  * +\n\nStop animations\n\n\n\n"
        },
        {
          "title": "MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update",
          "url": "https://ir.mediwound.com/news-releases/news-release-details/mediwound-reports-third-quarter-2024-financial-results-and",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.mediwound.com)\n\nMENU\n\nSearch:\n\nSearch for:\n\nMENU\n\n# Press Release Details\n\n## Website Notice Block\n\n## \n\nMediWound Reports Third Quarter 2024 Financial Results and Provides Company Update\n\nNovember 26, 2024\n\n[PDF Version](/node/11411/pdf)\n\n_EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025_\n\n_FDA Approves NexoBrid for Pediatric Use_\n\n_$25 Million Financing and ‚Ç¨16.25 Million EIC Funding Strengthen Cas_ _h Runway to Profitability_\n\n_NexoBrid Product Revenue Meets Expectations; Demand Exceeds Capacity as New Manufacturing Facility Commissioning Underway_\n\n_Conference Call Today, November 26 at 8:30 a.m. Eastern Time_\n\nYAVNE, Israel, Nov. 26, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update.\n\n‚ÄúWe made great headway toward our objectives this quarter, achieving a major milestone with NexoBrid approval for pediatric use in the U.S.,‚Äù said Ofer Gonen, Chief Executive Officer of MediWound. ‚ÄúWith the upcoming launch of the Phase 3 trial for EscharEx in venous leg ulcers, we‚Äôre advancing closer to addressing critical unmet needs in a $2 billion market. Additionally, we will be conducting a head-to-head Phase 2 study vs. collagenase in 2025, to further demonstrate EscharEx‚Äôs competitive advantage and maximize its commercial opportunity. We‚Äôre also accelerating our diabetic foot ulcer program with Phase 2/3 preparations well underway. Our manufacturing expansion remains on track, positioning us to meet the growing demand for NexoBrid globally.‚Äù\n\n**Third Quarter 2024 Highlights, Recent Developments and Upcoming Milestones:**\n\n**NexoBrid**\n\n  * Completed construction of the Company‚Äôs new, state-of-the-art GMP-compliant manufacturing facility with commissioning underway. The facility is expected to reach full operational capacity by the end of 2025, increasing manufacturing output sixfold. Commercial availability will depend on securing the necessary regulatory approvals.\n\n\n  * Received U.S. Food and Drug Administration (FDA) approval of NexoBrid for pediatric patients aged newborn through 18 with deep partial-thickness and/or full-thickness thermal burns. NexoBrid is now authorized for use in the U.S. for all age groups, aligning with its indications in the European Union and Japan.\n\n\n  * U.S. launch by Vericel continues to gain traction, with over 70 burn center Pharmacy and Therapeutics (P&T) committee submissions, of which approximately 50 have received approval and have placed initial orders. NexoBrid received a Category III CPT code, which will be posted on the AMA website on January 1, 2025, and will go into effect on July 1, 2025.\n\n\n  * The World Health Organization (WHO) has recently recognized enzymatic debridement as a validated treatment for burn injuries. This recognition, featured in the WHO‚Äôs _Standards and Recommendations for Burns Care in Mass Casualty Incidents (BMCI)_ guidelines for emergency medical teams, highlights NexoBrid‚Äôs critical role in emergency preparedness. It also bolsters efforts to implement strategic stockpiling plans within the European Union through the Health Emergency Preparedness and Response Authority (HERA), following the precedent set by the U.S. Biomedical Advanced Research and Development Authority (BARDA).\n\n\n  * The Company anticipates $20 million in total revenue for 2024, compared to prior guidance of $24 million. NexoBrid product revenues remain in line with expectations, driven by strong demand that exceeds current manufacturing capacity. Following FDA approval of NexoBrid‚Äôs pediatric indication without additional post-approval requirements, BARDA funding for further development is no longer required, reducing expected revenue from development services. Additionally, based on a Type C meeting with the FDA regarding the NexoBrid temperature-stable formulation project for the U.S. Army, clinical activities have been scheduled for 2026, which affects anticipated revenue from the U.S. Department of Defense for 2024.\n\n\n\n**EscharEx**\n\n  * The Phase 3 study of EscharEx for venous leg ulcers (VLUs) is set to commence, with FDA IND submission planned by year-end. All setup activities for initiation are complete, and the Company has successfully passed the required EMA inspection in preparation for the trial.\n\n\n  * The Company plans to host a virtual KOL event on January 8, 2025. The event will provide an update on the EscharEx VLU Phase 3 trial and review the commercial opportunity.\n\n\n  * Announced a planned randomized, head-to-head Phase 2 study of EscharEx vs. collagenase in VLU patients. Set to begin in 2025, the trial will support the EscharEx Biologics License Application (BLA) submission and strengthen the Company‚Äôs commercialization strategy. MediWound has secured additional R&D collaborations for this study with Solventum and M√∂lnlycke to optimize trial consistency and patient outcomes.\n\n\n  * Obtained ‚Ç¨16.25 million in funding from the European Innovation Council (EIC) for the clinical development of EscharEx for treating diabetic foot ulcers (DFUs). This will expedite MediWound's DFU program, and its associated revenue projections by four years. DFUs are more prevalent than VLUs, with a higher percentage of patients requiring debridement. Preparations for the DFU Phase 2/3 study are progressing as planned.\n\n\n\n**Corporate Development**\n\n  * Raised $25 million in a strategic private investment in public equity (PIPE) with several new and existing investors. M√∂lnlycke Health Care, a global leader in innovative wound care solutions, led the PIPE and entered into a collaboration agreement with MediWound.\n\n\n\n**Third Quarter 2024 Financial Highlights**\n\n  * **Revenue** : Revenue for the third quarter of 2024 totaled $4.4 million, compared to $4.8 million in the same period of 2023. The decrease was primarily due to lower revenue from BARDA development services.\n\n\n  * **Gross Profit** : Gross profit for the third quarter of 2024 was $0.7 million, representing 16% of total revenue, compared to $0.9 million, representing 19% of total revenue in the third quarter of 2023. This decline in gross margin reflects a shift in the revenue mix.\n\n\n  * **Expenditures** : \n    * **Research and Development** : R&D expenses for the quarter were $2.5 million, compared to $1.5 million in the third quarter of 2023. The increase was mainly due to costs associated with the EscharEx Phase 3 clinical trial.\n    * **Selling, General, and Administrative** : SG&A expenses for the third quarter of 2024 were $3.2 million, compared to $2.6 million in the same period of 2023. The increase was primarily from share-based compensation costs.\n\n\n  * **Operating Results** : Operating loss for the third quarter of 2024 was $5.1 million, compared to a loss of $3.0 million in the third quarter of 2023.\n\n\n  * **Net Loss** : Net loss for the third quarter of 2024 was $10.3 million, or $0.98 per share, compared to a net loss of $2.2 million, or $0.24 per share, in the third quarter of 2023. This change was primarily due to financial expenses driven by the revaluation of warrants.\n\n\n  * **Non-GAAP Adjusted EBITDA** : Adjusted EBITDA was a loss of $3.7 million, compared to a loss of $2.6 million in the third quarter of 2023.\n\n\n\n**Year-to-Date 2024 Financial Highlights**\n\n  * **Revenue:** Total revenues for the first nine months of 2024 reached $14.4 million, up from $13.3 million in the same period of 2023. The increase is mainly attributed to revenue contribution from Vericel.\n\n\n  * **Gross Profit** : Gross profit was $1.7 million, or 12% of total revenue, compared to $2.9 million, or 21% of total revenue, in the first nine months of 2023, reflecting changes in the revenue mix.\n\n\n  * **Expenditures** : \n    * **Research and Development** : R&D expenses were $5.9 million, slightly higher than $5.7 million in the same period of 2023.\n    * **Selling, General, and Administrative** : SG&A expenses totaled $9.1 million, compared to $8.8 million in the first nine months of 2023, driven primarily by increased share-based compensation costs.\n\n\n  * **Operating Results:** Operating loss for the first nine months of 2024 was $13.3 million, compared to $11.4 million in 2023.\n\n\n  * **Net Loss:** The net loss for the period was $26.3 million, or $2.72 per share, compared to a net loss of $5.0 million, or $0.56 per share, in the same period of 2023. This $21.3 million increase was mainly driven by net financial expenses, largely resulting from the revaluation of warrants due to a 78% rise in the Company‚Äôs share price year to date.\n\n\n  * **Adjusted EBITDA:** Adjusted EBITDA for the first nine months was a loss of $9.9 million, compared to a loss of $9.0 million in 2023.\n\n\n\n**Balance Sheet Highlights**\n\nAs of September 30, 2024, the Company had cash and cash equivalents and deposits totaling $46.0 million, compared to $42.1 million on December 31, 2023. During the first nine months of 2024, the Company raised $25 million through a PIPE offering, received $1.2 million from the exercise of Series A warrants, and fully settled its liability with Teva. The Company used $19.7 million to fund its operations in the first nine months of 2024, including $6.0 million allocated to CAPEX, primarily for facility scale-up.\n\n**Conference Call**\n\nMediWound management will host a conference call for investors on Tuesday, November 26, 2024, beginning at 8:30 a.m., Eastern Time to discuss these results. Shareholders and other interested parties may participate in the conference call by dialing 1-833-630-1956 (in the U.S.), 1-80-921-2373 (Israel), or 1-412-317-1837 (outside the U.S. & Israel). The call will be available via webcast by [clicking HERE](https://www.globenewswire.com/Tracker?data=WAjeaDlM_x64PHzsIogbzEV1Pnv5OBzU_syabYAIvNZ2MgyG4dctKwm27p7yECDNsAN9W3tOGOsnw16msKZQ913vGxv_7p9ExhRScXxzhFe8sG1SWdZG5Y7oM0y5Ruk0) or on the [Events & Presentations](https://www.globenewswire.com/Tracker?data=Io-jwu4cOqxKvr2fcbukejCqreGbw1lWAkdrXS_aeFfovdqlbMVpiehY4zApcDRUqatIMtbtxPWpix9ITBs2yxd-LrspDeNYqeJyXsn1MI4Hbpo17oTyj4-NywfTWTzeRGElMgEd394tfyt3lS1GUg==) page of Company‚Äôs website.\n\nA replay of the call will be available on the Company‚Äôs website at [www.mediwound.com](https://www.globenewswire.com/Tracker?data=SvpRtJZn5ZEnu5Lp_XmP3Wg7SJCODLCDnnia-NHxpK1QNpJUHpNgN1ejR-tdVDcXAedf8paeVDA5NFFPJToR50ujPxwDbwTtlY0NmMJ3Ov0=).\n\n**Non-IFRS Financial Measures**\n\nTo supplement consolidated financial statements prepared and presented in accordance with IFRS, the Company has provided a supplementary non-IFRS measure to consider in evaluating the Company‚Äôs performance. Management uses Adjusted EBITDA, which it defines as earnings before interest, taxes, depreciation and amortization, impairment, one-time expenses, restructuring and share-based compensation expenses.\n\nAlthough Adjusted EBITDA is not a measure of performance or liquidity calculated in accordance with IFRS, we believe the non-IFRS financial measures we present provide meaningful supplemental information regarding our operating results primarily because they exclude certain non-cash charges or items that we do not believe are reflective of our ongoing operating results when budgeting, planning and forecasting and determining compensation, and when assessing the performance of our business with our senior management.\n\nHowever, investors should not consider these measures in isolation or as substitutes for operating income, cash flows from operating activities or any other measure for determining the Company‚Äôs operating performance or liquidity that is calculated in accordance with IFRS. In addition, because Adjusted EBITDA is not calculated in accordance with IFRS, it may not necessarily be comparable to similarly titled measures employed by other companies. The non-IFRS measures included in this press release have been reconciled to the IFRS results in the tables below.\n\n**About MediWound**\n\nMediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.\n\nMediWound‚Äôs first drug, NexoBrid¬Æ, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx¬Æ, a promising candidate currently in Phase 3 development for the debridement of chronic wounds. Phase 2 clinical trials have shown EscharEx has distinct advantages over the current $360+ million market leader, presenting a unique opportunity for significant market growth.\n\nFor more information visit [www.mediwound.com](https://www.globenewswire.com/Tracker?data=SvpRtJZn5ZEnu5Lp_XmP3azT5AH0JlDL8hz5ykdHhvzKFI6D0n7rNh69Ur-zRo9YPXV3Td39uS4dP-MPVpKT843UOZSUuCw7d6eR7daRyQI=) and follow us on [LinkedIn](https://www.globenewswire.com/Tracker?data=3oKJShiERyOZR5y_gHRnYiBmNb7BzLrFK21-2hc8dwtVtxXLcBPiho655fxGFf-MjwruHUNXvsNfN82aOlJPjX8UT6svswC1cydoM0_3-hY=).\n\n**Cautionary Note Regarding Forward-Looking Statements**\n\nMediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as ‚Äúanticipates,‚Äù ‚Äúintends,‚Äù ‚Äúestimates,‚Äù ‚Äúplans,‚Äù ‚Äúexpects,‚Äù ‚Äúcontinues,‚Äù ‚Äúbelieve,‚Äù ‚Äúguidance,‚Äù ‚Äúoutlook,‚Äù ‚Äútarget,‚Äù ‚Äúfuture,‚Äù ‚Äúpotential,‚Äù ‚Äúgoals‚Äù and similar words or phrases, or future or conditional verbs such as ‚Äúwill,‚Äù ‚Äúwould,‚Äù ‚Äúshould,‚Äù ‚Äúcould,‚Äù ‚Äúmay,‚Äù or similar expressions.\n\nSpecifically, this press release contains forward-looking statements concerning the anticipated progress, development, study design, expected data timing, objectives anticipated timelines, expectations and commercial potential of our products and product candidates, including EscharEx¬Æ and NexoBrid¬Æ. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission by the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our products and products; our expectations regarding future growth, including our ability to develop new products; market acceptance of our products and product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future.\n\nThese and other significant factors are discussed in greater detail in MediWound‚Äôs annual report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (‚ÄúSEC‚Äù) on March 21, 2024 and Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound‚Äôs current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.\n\n**MediWound Contacts:**  \n---  \nHani Luxenburg| Daniel Ferry  \nChief Financial Officer | Managing Director  \nMediWound Ltd.| LifeSci Advisors, LLC  \nir@mediwound.com| daniel@lifesciadvisors.com  \n**Media Contact:**  \nEllie Hanson  \nFINN Partners for MediWound  \nellie.hanson@finnpartners.com  \n+1-929-588-2008  \n  \n**MediWound, Ltd.**  \n---  \n**Unaudited Condensed Consolidated Statements of Financial Position** U.S. dollars in thousands  \n**September 30,**| **December 31,**  \n**2024**| **2023**| **2023**  \n** _CURRENT ASSETS:_**  \nCash and cash equivalents and short-term deposits| 45,562| 45,523| 41,708  \nTrade and other receivable| 5,304| 4,071| 5,141  \nInventories| 3,022| 3,656| 2,846  \n**Total current assets**| **53,888**| **53,250**| **49,695**  \n** _NON-CURRENT ASSETS_**  \nTrade and other receivables| 50| 50| 233  \nLong-term restricted bank deposits| 434| 433| 440  \nProperty, plant and equipment, net| 13,453| 6,437| 9,228  \nRight of use assets, net| 6,793| 6,665| 6,698  \nIntangible assets, net| 116| 182| 165  \n**Total non-current assets**| **20,846**| **13,767**| **16,764**  \n**Total assets**| **74,734**| **67,017**| **66,459**  \n** _CURRENT LIABILITIES:_**  \nCurrent maturities of long-term liabilities| 726| 1,692| 1,410  \nWarrants, net| 19,056| 8,901| 7,296  \nTrade payables and accrued expenses| 3,131| 3,680| 5,528  \nOther payables| 2,664| 3,069| 3,891  \n**Total current liabilities**| **25,577**| **17,342**| **18,125**  \n** _NON- CURRENT LIABILITIES:_**  \nLiabilities in respect of IIA grants| 8,046| 7,860| 7,677  \nLiabilities in respect of TEVA| -| 2,394| 2,256  \nLease liabilities| 6,460| 5,935| 6,350  \nSeverance pay liability, net| 416| 436| 456  \n**Total non-current liabilities**| **14,922**| **16,625**| **16,739**  \nShareholders' equity| 34,235| 33,050| 31,595  \n**Total liabilities & shareholder equity**| **74,734**| **67,017**| **66,459**  \n  \n**MediWound, Ltd.**  \n---  \n**Unaudited Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss** U.S. dollars in thousands (except of share and per share data)  \n**Nine months ended**| **Three months ended**| **Year ended**  \n**September 30,**| **September 30,**| **December 31,**  \n**2024**| **2023**| **2024**| **2023**| **2023**  \nTotal Revenues| 14,382| 13,348| 4,355| 4,776| 18,686  \nCost of revenues| 12,651| 10,489| 3,678| 3,880| 15,108  \n**Gross profit**| **1,731**| **2,859**| **677**| **896**| **3,578**  \nResearch and development| 5,892| 5,659| 2,524| 1,533| 7,467  \nSelling and Marketing| 3,466| 3,635| 1,063| 1,197| 4,844  \nGeneral and administrative| 5,672| 5,185| 2,171| 1,415| 6,768  \nOther Income| -| (224)| -| (224)| (211)  \n**Total operating expenses**| **15,030**| **14,255**| **5,758**| **3,921**| **18,868**  \n**Operating loss**| **(13,299)**| **(11,396)**| **(5,081)**| **(3,025)**| **(15,290)**  \nFinancial income (expenses), net| (12,974)| 6,488| (5,180)| 877| 8,759  \nTaxes on income| (43)| (65)| (21)| (48)| (185)  \n**Net loss**| **(26,316)**| **(4,973)**| **(10,282)**| **(2,196)**| **(6,716)**  \nForeign currency translation adjustments| 3| (2)| (7)| 7| (13)  \n**Total comprehensive loss**| **(26,313)**| **(4,975)**| **(10,289)**| **(2,189)**| **(6,729)**  \n_Basic and diluted loss per share:_  \nNet loss per share| (2.72)| (0.56)| (0.98)| (0.24)| (0.75)  \nWeighted average number of ordinary shares| 9,679,599| 8,943,205| 10,511,288| 9,217,390| 9,013,144  \n  \n**MediWound, Ltd.**  \n---  \n**Unaudited Condensed Consolidated Statements of Cash Flows** U.S. dollars in thousands  \n**Nine months ended**| **Three months ended**| **Year Ended**  \n**September 30,**| **September 30,**| **December 31,**  \n**2024**| **2023**| **2024**| **2023**| **2023**  \n** _Cash Flows from Operating Activities:_**  \nNet loss| **(26,316****)**| **(4,973****)**| **(10,282****)**| **(2,196****)**| **(6,716****)**  \nAdjustments to reconcile net loss to net cash used in operating activities:  \n**Adjustments to profit and loss items:**  \nDepreciation and amortization| 1,086| 957| 361| 339| 1,303  \nShare-based compensation| 2,316| 1,642| 1,046| 311| 1,940  \nRevaluation of warrants accounted at fair value| 12,668| (6,705)| 4,661| (782)| (8,310)  \nRevaluation of liabilities in respect of IIA grants| 711| 709| 241| 217| 427  \nRevaluation of liabilities in respect of TEVA| 770| 357| 564| 116| 468  \nFinancing income (expenses) and exchange differences of lease liability| 238| (206)| 221| (184)| 257  \nIncrease (decrease) in severance liability, net| (46)| 80| (94)| 13| 83  \nOther income| -| (224)| -| (224)| (211)  \nFinancial income, net| (1,486)| (1,395)| (568)| (390)| (2,231)  \nUn-realized foreign currency (gain) loss| 74| 534| (4)| 68| 189  \n**16,331**| **(4,251****)**| **6,428**| **(516****)**| **(6,085****)**  \n**Changes in asset and liability items:**  \nDecrease (increase) in trade receivables| 285| 6,186| (468)| 71| 5,658  \nDecrease (increase) in inventories| (161)| (1,688)| 184| (526)| (906)  \nDecrease (increase) in other receivables| (283)| (198)| 291| (320)| (894)  \nDecrease in trade payables and accrued expenses| (1,948)| (1,687)| (48)| (51)| (594)  \nIncrease (decrease) in other payables| 105| (1,239)| 139| 287| (928)  \n**(2,002****)**| **1,374**| **98**| **(539****)**| **2,336**  \n**Net cash used in operating activities**| **(11,987****)**| **(7,850****)**| **(3,756****)**| **(3,251****)**| **(10,465****)**  \n  \n**Unaudited Condensed Consolidated Statements of Cash Flows** U.S. dollars in thousands  \n---  \n**Nine months ended**| **Three months ended**| **Year Ended**  \n**September 30,**| **September 30,**| **December 31,**  \n**2024**| **2023**| **2024**| **2023**| **2023**  \n** _Cash Flows from Investment Activities:_**  \nPurchase of property and equipment| (5,467)| (4,255)| (1,192)| (1,685)| (6,464)  \nInterest received| 1,588| 1,225| 461| 346| 1,947  \nInvestment in short term bank deposits, net| (9,346)| (36,319)| (13,555)| (4,489)| (29,804)  \n**Net cash used in investing activities**| **(13,225****)**| **(39,349****)**| **(14,286****)**| **(5,828****)**| **(34,321****)**  \n**_Cash Flows from Financing Activities:_**  \nRepayment of lease liabilities| (686)| (574)| (228)| (240)| (778)  \nProceeds from exercise of warrants| 1,210| -| 600| -| -  \nProceeds from issuance of shares and warrants, net| 22,436| 24,909| 22,436| -| 24,909  \nRepayments of IIA grants, net| (219)| (380)| (99)| (70)| (380)  \nRepayment of liabilities in respect of TEVA| (2,834)| (834)| (2,000)| (417)| (834)  \n**Net cash provided by (used in) financing activities**| **19,907**| **23,121**| **20,709**| **(727****)**| **22,917**  \nExchange rate differences on cash and cash equivalent balances| **(86****)**| **(538****)**| **18**| **(81****)**| **(160****)**  \nIncrease (decrease) in cash and cash equivalents| **(5,391****)**| **(24,616****)**| **2,685**| **(9,887****)**| **(22,029****)**  \nBalance of cash and cash equivalents at the beginning of the period| 11,866| 33,895| 3,790| 19,166| 33,895  \n**Balance of cash and cash equivalents at the end of the period**| **6,475**| **9,279**| **6,475**| **9,279**| **11,866**  \n  \n**MediWound Ltd.****Adjusted EBITDA** U.S. dollars in thousands  \n---  \n**Nine months ended**| **Three months ended**| **Year Ended**  \n**September 30,**| **September 30,**| **December 31,**  \n**2024**| **2023**| **2024**| **2023**| **2023**  \n**Net loss**| **(26,316****)**| **(4,973****)**| **(10,282****)**| **(2,196****)**| **(6,716****)**  \nAdjustments:  \nFinancial income (expenses), net| (12,974)| 6,488| (5,180)| 877| 8,759  \nOther Income, net| -| 224| -| 224| 211  \nTaxes on income| (43)| (65)| (21)| (48)| (185)  \nDepreciation and amortization| (1,086)| (957)| (361)| (339)| (1,303)  \nShare-based compensation expenses| (2,316)| (1,642)| (1,046)| (311)| (1,940)  \nTotal adjustments| (16,419)| 4,048| (6,608)| 403| 5,542  \n**Adjusted EBITDA**| **(9,897****)**| **(9,021****)**| **(3,674****)**| **(2,599****)**| **(12,258****)**  \n  \n![](https://ml.globenewswire.com/media/OWU0Mzg3MmItOThkNi00ZmRmLWJjYWMtYTI0YmRmMTBjZTMzLTEwMjg0MzQ=/tiny/MediWound-Ltd-.png)\n\n  * [Print Page]()\n\nPrint Page\n\n  * [Email Alerts](/email-alerts)\n\nEmail Alerts\n\n  * [IR Search](/search)\n\nIR Search\n\n\n\n\nCookie Consent\n\nBy continuing browsing, you agree to the storing of cookies on your device to enhance your site experience and for analytical purposes. To learn more about how we use the cookies, please see our [Cookie Policy](https://www.mediwound.com/cookie-policy/). \n\nI AGREE\n\nAccesi _b_ ility\n\n  * X+-\n\nFonts size\n\n  * +\n\nUnderline links\n\n  * +\n\nBigger tabs outline\n\n  * +\n\nDark contrast\n\n  * +\n\nBright contrast\n\n  * +\n\nSimple font\n\n  * +\n\nDyslexic font\n\n  * +\n\nStop animations\n\n\n\n"
        }
      ]
    },
    {
      "section_name": "Investor Presentation",
      "links": [
        {
          "title": "MediWound Company Presentation - November 2024",
          "url": "https://ir.mediwound.com/static-files/08f1f9ca-3b02-4735-a8a0-c2ab56e25982",
          "content": "\n"
        }
      ]
    }
  ]
}